Proteomic analysis of cases with pancreatic cancer who undergo preoperative chemoradiation therapy
Not Applicable
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000014698
- Lead Sponsor
- Yokohama City University, department of Gastroenterological Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
The cases which are judged unsuitable by the doctors in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are identified through proteomic profiling in JPRN-UMIN000014698 pancreatic cancer chemoradiation study?
How does proteomic data from JPRN-UMIN000014698 compare to standard-of-care chemoradiation in pancreatic ductal adenocarcinoma?
Which proteomic biomarkers in JPRN-UMIN000014698 predict response to preoperative chemoradiation in pancreatic cancer patients?
What adverse events are associated with preoperative chemoradiation in JPRN-UMIN000014698 and how are they managed?
Are there combination therapies with proteomic targets from JPRN-UMIN000014698 for pancreatic cancer treatment?